Finnrick, an independent testing programme, publishes 4 assays for SYS Pharma Corp: 3 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 1 did not. Most recent assay 13 Jul 2026.
SYS Pharma Corp operates from China, listed by Finnrick as "Trading". Source: Finnrick, https://www.finnrick.com/vendors/sys-pharma-corp.
SYS Pharma Corp is listed as active.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 4 | 3 passed, 1 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
These details were read from SYS Pharma Corp's own website on 2026-08-17. Pages consulted:
SYS Pharma Corp is listed as active and we hold 4 Finnrick assays (3 passing, 1 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 4 assays for SYS Pharma Corp: 3 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 1 did not. Most recent assay 13 Jul 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Taikangbio Peptides Review, Taishijie Peptides Review, TCI Peptides Review.